Analyzing genetic factors in inflammatory bowel disease across different populations
Genome Analysis Across Populations in Inflammatory Bowel Disease
Mount Sinai Hospital, Canada · NCT06042387
This study is trying to find out how genes and the environment affect inflammatory bowel disease by looking at samples from people with the condition and healthy individuals.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Sex | All |
| Sponsor | Mount Sinai Hospital, Canada (other) |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT06042387 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the genetic and environmental factors contributing to inflammatory bowel disease (IBD) by analyzing clinical data and genome samples from affected individuals and healthy controls. Participants will provide blood or saliva samples to facilitate genetic analysis. The study seeks to identify susceptible genes that may play a role in the pathogenesis of IBD, which includes conditions like Crohn's disease and ulcerative colitis. By understanding these factors, the research hopes to shed light on the increasing incidence of IBD across various populations.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, as well as healthy controls without any history of IBD.
Not a fit: Patients with other gastrointestinal conditions that do not meet the criteria for IBD or healthy controls may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of inflammatory bowel diseases, potentially guiding personalized treatment strategies.
How similar studies have performed: Other studies have shown success in identifying genetic factors associated with inflammatory bowel diseases, suggesting that this approach is promising and builds on existing knowledge.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects: diagnosed with Inflammatory Bowel Disease (Crohn's disease, ulcerative colitis, IBD-undetermined) * Available medical records to confirm IBD diagnosis (Crohn's disease, Ulcerative colitis, IBD undetermined (IBD-U)) * Healthy controls: no personal history of IBD, no family history of IBD, no history of unexplained chronic diarrhea/blood in stool/anemia/abdominal pain/weight loss * Any age Exclusion Criteria: \- Subjects with other gastrointestinal conditions not meeting the above IBD or Healthy Control criteria
Where this trial is running
Toronto, Ontario
- Sinai Health System — Toronto, Ontario, Canada (RECRUITING)
Study contacts
- Principal investigator: Mark Silverberg, MD PhD — Sinai Health System
- Study coordinator: Joanne Stempak, MSc
- Email: joanne.stempak@sinaihealth.ca
- Phone: 4165864800
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Ulcerative Colitis, Healthy, Crohn Disease, Inflammatory Bowel Diseases